Your allergy
What is allergy
House dust mite allergy
Pollen allergy
Living with allergy
Socio-economic impact
What is allergic asthma
How is allergy diagnosed
Treating allergy
Our solutions
Consumer healthcare
Diagnostics
Allergy vaccines
Production and quality
Emergency medicine
Our science
Scientific focus
Science & technology
Pipeline
Digital innovation
Collaboration & partnerships
Healthcare Professionals
Allergy immunotherapy
Our data
Clinical trials
Real-world evidence
Clinical data sharing
Henning Løwenstein Research Award
Symposium on Specific Allergy
Medical events
Our company
Newsroom
Stories
Strategy
Privacy
Global presence
Organisation
History
Owners
Sustainability
Environmental
Social
Governance
Investors
Overview
Financial reporting
Risk management
Reporting standards
Auditors
Governance
IR policy
Executive Leadership Team
Board of directors
News & Events
Company releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024
The Share
Dividend history
Analyst coverage
Analyst estimates
Shareholder information
Authorizations
ADR Programme
Contact IR
Annual general meeting
Annual general meeting (DK)
Capital Markets Day 2024
Careers
Working at ALK
Vacant positions
Cultural Beliefs
Select country
Fulltext search
Search
ALK’s pivotal phase 3 trial in children published in reputable scientific journal
Link
https://www.globenewswire.com/news-release/2024/11/27/2988155/0/en/ALK-s-pivota…
Created date
Wed, 11/27/2024 - 12:00
Nasdaq ID
2988155
Last updated:
14.02.2025
